CONTENTS

        Chapters
  1. Background
  2. IUD Performance
  3. Insertion
  4. Removal
  5. Infection
  6. Worldwide Use
  7. IUDs in Family Planning Programs

HIGHLIGHTS

Published by the Population Information Program, Center for Communication Programs, The Johns Hopkins School of Public Health, 111 Market Place, Suite 310, Baltimore, Maryland 21202-4012, USA

Volume XXIII, Number 5
December 1995
Infection

Overall, women using IUDs are about twice as likely to develop pelvic inflammatory disease (PID) as women using no contraception, according to most studies. These studies have involved women with both high and low risk of sexually transmitted diseases (STDs), which cause PID (41, 78, 81, 209, 265, 421). This increased risk of PID is largely concentrated in the first few weeks after insertion and is due to poor infection prevention during insertion. Thereafter, the risk is among women exposed to STDs. Thus, for women in mutually faithful sexual relationships, IUDs pose little ongoing risk of PID (208, 227, 507).

Pelvic inflammatory disease is a broad term for any infection ascending from the cervix into the uterus, fallopian tubes, and ovaries (422). PID is fairly common in developed countries. About 1% to 2% of all women of reproductive age develop PID each year (30, 421, 532). In developing countries the incidence is unknown but may be higher in some areas (244, 302). In addition to STDs, postpartum and postabortion infections are major causes of PID (464).

The complications of PID sometimes are severe. Even a single infection can permanently damage the lining of the fallopian tubes. This may partially or totally block one or both tubes, substantially increasing the chances of ectopic pregnancy andinfertility (136, 369, 421, 424). With each episode of PID the chances of tubal blockage and infertility increase (422). A woman who has had PID is more likely to have chronic pelvic pain than other women and is more susceptible to repeated infections (422). All these complications are most likely if PID is not treated promptly and appropriately (see Population Reports, Controlling Sexually Transmitted Diseases, L-9, June 1993).


Previous | Next
Top of Page | Table of Contents

111 Market Place, Suite 310, Baltimore, MD 21202, USA
Phone: (410) 659.6300/Fax: (410) 659.6266/E-mail: Poprepts@jhuccp.org

Population Reports